Nesfatin-1 in cardiovascular orchestration: From bench to bedside.


Journal

Pharmacological research
ISSN: 1096-1186
Titre abrégé: Pharmacol Res
Pays: Netherlands
ID NLM: 8907422

Informations de publication

Date de publication:
06 2020
Historique:
received: 15 01 2020
revised: 09 03 2020
accepted: 18 03 2020
pubmed: 24 3 2020
medline: 23 4 2021
entrez: 24 3 2020
Statut: ppublish

Résumé

Since the discovery of Nesfatin-1 in 2006, intensive research was finalized to further and deeper investigate the precise physiological functions of the peptide at both central and peripheral levels, rapidly enriching the knowledge regarding this intriguing molecule. Nesfatin-1 is a hypothalamic peptide generated via the post-translational processing of its precursor Nucleobindin 2, a protein supposed to play a role in many biological processes thanks to its ability to bind calcium and to interact with different intracellular proteins. Nesfatin-1 is mainly known for its anorexic properties, but it also controls water intake and glucose homeostasis. Recent experimental evidences describe the peptide as a possible direct/indirect orchestrator of central and peripheral cardiovascular control. A specific Nesfatin-1 receptor still remains to be identified although numerous studies suggest that the peptide activates extra- and intracellular regulatory pathways by involving several putative binding sites. The present paper was designed to systematically review the latest findings about Nesfatin-1, focusing on its cardiovascular regulatory properties under normal and physiopathological conditions. The hope is to provide the conceptual basis to consider Nesfatin-1 not only as a pleiotropic neuroendocrine molecule, but also as a homeostatic modulator of the cardiovascular function and with a crucial role in cardiovascular diseases.

Identifiants

pubmed: 32201244
pii: S1043-6618(20)30184-5
doi: 10.1016/j.phrs.2020.104766
pii:
doi:

Substances chimiques

Biomarkers 0
NUCB2 protein, human 0
Nucleobindins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

104766

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest All the authors declared that they have no conflicts of interest.

Auteurs

Tommaso Angelone (T)

Laboratory of Cellular and Molecular Cardiovascular Patho-physiology, Dept of Biology, Ecology and Earth Sciences, University of Calabria, Rende, CS, Italy; National Institute of Cardiovascular Research I.N.R.C., Bologna, Italy. Electronic address: tommaso.angelone@unical.it.

Carmine Rocca (C)

Laboratory of Cellular and Molecular Cardiovascular Patho-physiology, Dept of Biology, Ecology and Earth Sciences, University of Calabria, Rende, CS, Italy.

Teresa Pasqua (T)

Laboratory of Cellular and Molecular Cardiovascular Patho-physiology, Dept of Biology, Ecology and Earth Sciences, University of Calabria, Rende, CS, Italy. Electronic address: teresa.pasqua@unical.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH